カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の吸入可能医薬品市場2023-2030：薬剤クラス別（エアゾール、ドライパウダー製剤、スプレー）、用途別（呼吸器疾患、非呼吸器疾患）、地域別

【英語タイトル】Inhalable Drugs Market Size, Share & Trends Analysis Report By Drug Class (Aerosol, Dry Powder Formulation, Spray), By Application (Respiratory & Non-Respiratory Diseases), By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV150）・商品コード：GRV23NOV150
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：80
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：医薬品
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥868,700見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,014,700見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,306,700見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

吸入可能医薬品市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界の吸入可能医薬品市場規模は2030年までに524億米ドル以上に達する見込みで、2023年から2030年までのCAGRは6.6%を記録します。呼吸器疾患の有病率の上昇と高齢者人口の増加が、市場を牽引すると予想される主な要因の一部です。慢性閉塞性肺疾患（COPD）は生命を脅かす呼吸器疾患で、世界的に死因の第3位になると予測されています。このため、吸入可能な薬剤の需要が高まります。

Global Burden of Disease調査によると、2016年には世界で251百万人のCOPD患者が報告されました。それゆえ、吸入可能な新薬を開発する必要性が高まっています。例えば、2019年1月、Verona PharmaはCOPDを適応症とするEnsifentrineの開発でWHOの承認を受け、臨床試験のフェーズIIを完了しました。

吸入可能な薬剤の進歩は、吸入可能な薬剤市場を推進すると予想されます。ナノ粒子は、先進的な吸入可能医薬品の開発のために研究されています。例えば、2019年4月、クイーンズランド工科大学の科学者は、肺がんの吸入粉末を装填したキトサンナノ粒子を使用した研究を実施しました。これらのナノ粒子は下気道を容易に透過し、血流に拡散することができます。

糖尿病やパーキンソン病などの非呼吸器疾患の有病率の上昇も、市場を牽引すると予想されます。そのため、メーカーは費用対効果の高い革新的な吸入式薬剤を開発しています。例えば、2019年1月には、MannKind Corporationが糖尿病患者向けにAfrezzaを開発・商品化しました。

強力なパイプライン医薬品の存在は、市場成長を後押しすると推定される主要因の1つと考えられています。臨床試験中のプロジェクトは世界全体で220以上あります。例えば、GlaxoSmithKlineの喘息治療薬Fluticasone Furoate/Vilanterol/Umeclidinium Bromideの3剤併用療法はフェーズIII段階にあり、予測期間中に上市される見込みです。

企業は、製品ポートフォリオを拡大し、市場でより強力な足場を得るために、提携、M&A、パートナーシップ、認知度向上プログラムなどの戦略的イニシアチブを取っています。例えば、2019年7月、Cipla, Inc.は上海を拠点とするJiangsu Acebright Pharmaceuticalsと合弁会社を設立し、中国に呼吸器製品を製造する会社を設立しました。

吸入可能医薬品市場レポートハイライト

- 製品別では、密度が低く、吸入器で容易に分散できるなどの利点から、2022年の吸入性医薬品市場は乾燥粉末製剤分野が支配的でした。。

- 用途別では、喘息やCOPDの有病率の高さから、呼吸器疾患が2022年の売上高で最大の市場シェアを占めました。非呼吸器疾患セグメントは、様々な神経疾患の管理における高い機会のため、急速なペースで成長しています。

- 北米は、確立された製薬業界と医療施設、および吸入器の使用に関する意識の高まりが原動力となり、2022年の吸入可能な薬剤の世界市場で主導的地位を維持しました。アジア太平洋市場は予測期間中に最も速い成長を示すと予測されています。

- この業界の主要企業には、AstraZeneca社、Vectura社、Cipla Inc.社、GlaxoSmithKline社、Novartis社、Mundipharma社、Boehringer Ingelheim International GmbH社、Mylan社などがあります。

第1章 調査方法・範囲
第2章 エグゼクティブサマリー
第3章 世界の吸入可能医薬品市場変数・傾向・範囲
第4章 世界の吸入可能医薬品市場：薬剤クラス別予測・傾向分析
第5章 世界の吸入可能医薬品市場：用途別予測・傾向分析
第6章 世界の吸入可能医薬品市場：地域別予測・傾向分析
第7章 競争状況

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Drug Class
1.1.2. Application
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug class outlook
2.2.2. Application outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Inhalable Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Inhalable Drugs Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Inhalable Drugs: Drug Class Estimates & Trend Analysis
4.1. Inhalable Drugs Market: Key Takeaways
4.2. Inhalable Drugs Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Aerosol
4.3.1. Aerosol market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Dry Powder Formulation
4.4.1. Dry powder formulation market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Spray
4.5.1. Spray market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Inhalable Drugs: Application Estimates & Trend Analysis
5.1. Inhalable Drugs Market: Key Takeaways
5.2. Inhalable Drugs Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Respiratory Diseases
5.3.1. Respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Non-respiratory Diseases
5.4.1. Non-respiratory diseases market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Inhalable Drugs Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Inhalable Drugs Market by Region: Key Takeaways
6.3. North America
6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.6. Denmark
6.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.7. Sweden
6.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.4.8. Norway
6.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. South Africa
6.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.2. Saudi Arabia
6.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. AstraZeneca
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Sanofi
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Vectura Group Ltd
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Viatris Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. GSK plc.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Mundipharma International.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Boehringer Ingelheim International GmbH.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Cipla Inc.
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 3 North America inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 4 North America inhalable drugs market, by region, 2018 - 2030 (USD Million)
Table 5 U.S. inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 6 U.S. inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 7 Canada inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 8 Canada inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 9 Europe inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 10 Europe inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 11 Europe inhalable drugs market, by region, 2018 - 2030 (USD Million)
Table 12 Germany inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 13 Germany inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 14 UK inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 15 UK inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 16 France inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 17 France inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 18 Italy inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 19 Italy inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 20 Spain inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 21 Spain inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 22 Denmark inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 23 Denmark inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 24 Sweden inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 25 Sweden inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 26 Norway inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 27 Norway inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 28 Asia Pacific inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 29 Asia Pacific inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 30 Asia Pacific inhalable drugs market, by region, 2018 - 2030 (USD Million)
Table 31 Japan inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 32 Japan inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 33 China inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 34 China inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 35 India inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 36 India inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 37 Australia inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 38 Australia inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 39 Thailand inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 40 Thailand inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 41 South Korea inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 42 South Korea inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 43 Latin America inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 44 Latin America inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 45 Latin America inhalable drugs market, by region, 2018 - 2030 (USD Million)
Table 46 Brazil inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 47 Brazil inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 48 Mexico inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 49 Mexico inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 50 Argentina inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 51 Argentina inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 52 Middle East and Africa inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 53 Middle East and Africa inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 54 Middle East and Africa inhalable drugs market, by region, 2018 - 2030 (USD Million)
Table 55 South Africa inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 56 South Africa inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 57 Saudi Arabia inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 58 Saudi Arabia inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 59 UAE inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 60 UAE inhalable drugs market, by application, 2018 - 2030 (USD Million)
Table 61 Kuwait inhalable drugs market, by drug class, 2018 - 2030 (USD Million)
Table 62 Kuwait inhalable drugs market, by Application, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Inhalable drugs: Market outlook
Fig. 9 Inhalable drugs: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Inhalable drugs market driver impact
Fig. 15 Inhalable drugs market restraint impact
Fig. 16 Inhalable drugs market strategic initiatives analysis
Fig. 17 Inhalable drugs market: Drug class movement analysis
Fig. 18 Inhalable drugs market: Drug class outlook and key takeaways
Fig. 19 Aerosol market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Dry powder formulation market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Spray market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Inhalable drugs market: Application movement analysis
Fig. 23 Inhalable drugs market: Application outlook and key takeaways
Fig. 24 Respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Non-respiratory diseases market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Global inhalable drugs market: Regional movement analysis
Fig. 27 Global inhalable drugs market: Regional outlook and key takeaways
Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 UK market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 France market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 42 China market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 43 India market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 53 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)

★調査レポート[世界の吸入可能医薬品市場2023-2030：薬剤クラス別（エアゾール、ドライパウダー製剤、スプレー）、用途別（呼吸器疾患、非呼吸器疾患）、地域別] (コード：GRV23NOV150)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の吸入可能医薬品市場2023-2030：薬剤クラス別（エアゾール、ドライパウダー製剤、スプレー）、用途別（呼吸器疾患、非呼吸器疾患）、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の経鼻薬物送達技術市場（2023-2033)：容器別（加圧容器、非加圧容器）、投与方法別（2回点鼻、複数回点鼻、単回点鼻）、剤形別（点鼻スプレー、点鼻液・液体、点鼻ジェル、点鼻粉末、その他）、用途別（呼吸器疾患、非呼吸器疾患）、エンドユーザー別（在宅医療、病院、専門クリニック、その他）、地域別
  • 世界の大腸がん治療薬市場2023-2030：薬剤クラス別（化学療法、免疫療法）、地域別（北米、アジア太平洋、中南米、ヨーロッパ）
  • 世界の自動車用芳香剤市場予測2023-2029：ジェル&缶、スプレー&エアゾール、その他
  • 世界の喘息治療薬市場2023-2030：薬剤クラス別（抗炎症薬、併用療法）、製品別（吸入器、ネブライザー）、投与経路別、地域別
  • 世界の光線性角化症治療市場2023-2030：治療法別（外用、手術、光線力学的療法）、薬剤クラス別、エンドユーザー別、地域別
  • 世界の降圧薬市場2024-2030：薬剤クラス別（利尿薬、ACE阻害薬）、種類別（一次、二次）、投与経路別、流通チャネル別、地域別
  • 世界の多形膠芽腫治療市場2023-2030：治療別（放射線療法、免疫療法）、薬剤クラス別、エンドユーザー別、地域別
  • 世界の局所創傷薬市場2023-2030：製品別（クリーム、ジェル、スプレー、その他）、用途別（慢性創傷、急性創傷）、エンドユーザー別、地域別
  • 世界の抗真菌薬市場2024-2030：薬剤クラス別（アゾール系、ポリエン系）、効能・効果別（皮膚糸状菌症、アスペルギルス症）、剤形別、販売チャネル別、地域別

    • ◆H&Iグローバルリサーチのお客様（例）◆